 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...203204205206207208209210211212213...235236» |
- 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 6, 2015
P2, N=43, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Nov 2015 --> Jun 2016
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: Phase I Trial of Combination of FOLFIRI and SOM 230 (clinicaltrials.gov) - Dec 6, 2015
P1, N=16, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Nov 2015 --> Jun 2016 Trial primary completion date: Feb 2016 --> Jun 2016
- Avastin (bevacizumab) / Roche
Biomarker: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Dec 5, 2015
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2016 --> Jun 2016 Trial primary completion date: Dec 2015 --> Mar 2016
- Enrollment change: Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor (clinicaltrials.gov) - Dec 5, 2015
P2, N=0, Withdrawn, Sponsor: New York University School of Medicine
Trial primary completion date: Dec 2015 --> Mar 2016 N=96 --> 0
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Study of REOLYSIN (clinicaltrials.gov) - Dec 5, 2015
P1, N=32, Recruiting, Sponsor: Oncolytics Biotech
N=96 --> 0 N=20 --> 32 | Trial primary completion date: Jun 2016 --> Dec 2016
- ||| AZD0156 / AstraZeneca
Enrollment open, Combination therapy, Monotherapy, PARP Biomarker, Metastases: AToM: Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (clinicaltrials.gov) - Dec 5, 2015
P1, N=225, Recruiting, Sponsor: AstraZeneca
N=20 --> 32 | Trial primary completion date: Jun 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment closed: Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Dec 5, 2015
P2, N=33, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 4, 2015
P2, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: May 2018 --> Sep 2017
- | Trial initiation date, Trial primary completion date: ESOPEC: Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (clinicaltrials.gov) - Dec 3, 2015
P3, N=438, Not yet recruiting, Sponsor: University Hospital Freiburg
Trial primary completion date: May 2018 --> Sep 2017 Initiation date: Oct 2015 --> Jan 2016 | Trial primary completion date: Oct 2021 --> Jan 2022
- ||||| Avastin (bevacizumab) / Roche
New P1/2 trial, Combination therapy, Metastases: FABLOx: Study of 5-fluorouracil (5-FU), Nab (clinicaltrials.gov) - Dec 3, 2015
P1/2, N=78, Not yet recruiting, Sponsor: Celgene Corporation
- EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
New P1/2 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: NCI-2015-01942: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 3, 2015
P1/2, N=43, Not yet recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
New P1 trial, PD(L)-1 Biomarker, Metastases: Study of Pembrolizumab With REOLYSIN (clinicaltrials.gov) - Dec 3, 2015
P1, N=9, Not yet recruiting, Sponsor: Oncolytics Biotech
- ||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
Trial completion, Combination therapy, Surgery: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer (clinicaltrials.gov) - Dec 3, 2015
P3, N=3348, Completed, Sponsor: Hoffmann-La Roche
Initiation date: Oct 2015 --> Jan 2016 | Trial primary completion date: Oct 2021 --> Jan 2022 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: Second Look Laparoscopy in Colorectal Cancer (clinicaltrials.gov) - Nov 30, 2015
P2, N=140, Recruiting, Sponsor: National Cancer Institute, Naples
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Jun 2016
- conatumumab (AMG 655) / Amgen
Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Nov 27, 2015
P2, N=12, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Jul 2016
- Trial suspension, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Nov 25, 2015
P2, N=26, Suspended, Sponsor: University of Miami
Trial primary completion date: Dec 2015 --> Jul 2016 Recruiting --> Suspended
- ||| erlotinib / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Trial primary completion date, Metastases: Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Nov 24, 2015
P2, N=150, Active, not recruiting, Sponsor: Ludwig-Maximilians - University of Munich
Recruiting --> Suspended Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jul 2015
- |||| MB-6 / Microbio
Trial primary completion date, Surgery: A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer. (clinicaltrials.gov) - Nov 24, 2015
P3, N=184, Recruiting, Sponsor: Microbio Co Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jul 2015 Trial primary completion date: Dec 2015 --> Dec 2017
- Vectibix (panitumumab) / Amgen
Enrollment closed: Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques (clinicaltrials.gov) - Nov 19, 2015
P2, N=82, Active, not recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Trial primary completion date: Dec 2015 --> Dec 2017 Recruiting --> Active, not recruiting
- Removab (catumaxomab) / NeoPharm, Trion Pharma
Trial primary completion date: Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas (clinicaltrials.gov) - Nov 17, 2015
P2, N=42, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2015 --> Mar 2016
- New P2/3 trial, Surgery: Surgery Plus Single Agent Chemotherapy Versus Primary Chemotherapy for Gestational Trophoblastic Neoplasms (clinicaltrials.gov) - Nov 17, 2015
P2/3, N=20, Recruiting, Sponsor: Maher elesawi kamel elesawi
- | NN1213 / Novo Nordisk
Trial completion, Metastases: Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Nov 16, 2015
P2, N=146, Completed, Sponsor: Radiation Therapy Oncology Group
Trial primary completion date: Oct 2015 --> Mar 2016 Active, not recruiting --> Completed
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial, Combination therapy, Metastases: Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 16, 2015
P3, N=550, Recruiting, Sponsor: AB Science
- leucovorin calcium / Generic mfg.
Trial termination, Trial primary completion date: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Nov 15, 2015
P2, N=160, Terminated, Sponsor: University of Arkansas
Active, not recruiting --> Completed Suspended --> Terminated | Trial primary completion date: Sep 2017 --> Jun 2015; Non-compliance
- |||| Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Combination therapy, Metastases: A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan (clinicaltrials.gov) - Nov 15, 2015
P2, N=62, Completed, Sponsor: Sanofi
Suspended --> Terminated | Trial primary completion date: Sep 2017 --> Jun 2015; Non-compliance Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date: RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma (clinicaltrials.gov) - Nov 15, 2015
P1/2, N=47, Completed, Sponsor: University of Utah
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Aug 2015
- Trial primary completion date: A Phase II Study of Neoadjuvant FOLFIRINOX (clinicaltrials.gov) - Nov 14, 2015
P2, N=48, Recruiting, Sponsor: Safi Shahda
Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Aug 2015 Trial primary completion date: Jul 2016 --> Dec 2016
- ||||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion, Metastases: NAPOLI-1: Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Nov 12, 2015
P3, N=405, Completed, Sponsor: Merrimack Pharmaceuticals
Trial primary completion date: Jul 2016 --> Dec 2016 Active, not recruiting --> Completed
- || Stivarga (regorafenib) / Bayer
Trial primary completion date: Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX (clinicaltrials.gov) - Nov 11, 2015
P2, N=264, Recruiting, Sponsor: US Oncology Research
Active, not recruiting --> Completed Trial primary completion date: Sep 2019 --> Mar 2017
- | Trial completion, Trial initiation date, Trial primary completion date, Metastases: Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia (clinicaltrials.gov) - Nov 10, 2015
P2, N=38, Completed, Sponsor: Translational Oncology Research International
Trial primary completion date: Sep 2019 --> Mar 2017 Active, not recruiting --> Completed | Initiation date: Apr 2008 --> Dec 2007 | Trial primary completion date: Jun 2013 --> Jun 2011
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) (clinicaltrials.gov) - Nov 10, 2015
P=N/A, N=720, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Initiation date: Apr 2008 --> Dec 2007 | Trial primary completion date: Jun 2013 --> Jun 2011 Trial primary completion date: Mar 2016 --> Oct 2016
- || ipatasertib (RG7440) / Roche
Enrollment closed, Combination therapy, Metastases: Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Nov 10, 2015
P1, N=118, Active, not recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Mar 2016 --> Oct 2016 Recruiting --> Active, not recruiting
- leucovorin calcium / Generic mfg., temozolomide / Generic mfg.
Trial primary completion date, Combination therapy: FOLAGLI: Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma (clinicaltrials.gov) - Nov 9, 2015
P1, N=44, Recruiting, Sponsor: Institut Cancerologie de l'Ouest
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2014 --> Mar 2017
- |||||| andecaliximab (GS-5745) / Gilead
Enrollment open, Trial primary completion date, Metastases: GAMMA-1: Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Nov 8, 2015
P3, N=430, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Oct 2014 --> Mar 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2018 --> Sep 2018
- |||| HyperAcute Pancreas (algenpantucel-L) / Lumos Pharma
Trial primary completion date, Metastases: Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov) - Nov 1, 2015
P3, N=280, Recruiting, Sponsor: NewLink Genetics Corporation
Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2018 --> Sep 2018 Trial primary completion date: Sep 2015 --> Dec 2016
- New P1 trial: Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma (clinicaltrials.gov) - Oct 30, 2015
P1, N=24, Recruiting, Sponsor: The University of Texas Health Science Center, Houston
- || oxaliplatin / Generic mfg.
New P2/3 trial: Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy (clinicaltrials.gov) - Oct 29, 2015
P2/3, N=64, Recruiting, Sponsor: Jiangsu Province Hospital of Traditional Chinese Medicine
- Avastin (bevacizumab) / Roche
New P2 trial: CARCINOSIS: Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer (clinicaltrials.gov) - Oct 29, 2015
P2, N=30, Not yet recruiting, Sponsor: Thomas Bachleitner-Hofmann, MD
- |||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, Metastases: MM-398-07-02-03: Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Oct 28, 2015
P2, N=168, Recruiting, Sponsor: Merrimack Pharmaceuticals
Trial primary completion date: Sep 2015 --> Dec 2016 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Trial primary completion date, Surgery: Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer (clinicaltrials.gov) - Oct 27, 2015
P2, N=43, Recruiting, Sponsor: University of Southern California
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2015 --> Jul 2016
- ||| Avastin (bevacizumab) / Roche
Biomarker, Enrollment closed, Metastases: Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 27, 2015
P2, N=52, Active, not recruiting, Sponsor: CR-CSSS Champlain-Charles-Le Moyne
Trial primary completion date: Jul 2015 --> Jul 2016 Recruiting --> Active, not recruiting
- ||| AZD0156 / AstraZeneca
New P1 trial, Combination therapy, Monotherapy, PARP Biomarker, Metastases: AToM: Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (clinicaltrials.gov) - Oct 27, 2015
P1, N=225, Not yet recruiting, Sponsor: AstraZeneca
- GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy, Metastases: FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 23, 2015
P2, N=92, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2017 --> Nov 2018
- || napabucasin (BBI608) / Sumitomo Pharma
Trial primary completion date, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer (clinicaltrials.gov) - Oct 22, 2015
P1, N=64, Recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Nov 2017 --> Nov 2018 Trial primary completion date: Dec 2015 --> Jun 2016
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Oct 22, 2015
P2, N=50, Recruiting, Sponsor: howard safran
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Sep 2015 --> Sep 2016
- || napabucasin (BBI608) / Sumitomo Pharma
Trial primary completion date, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Oct 22, 2015
P1, N=144, Recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Trial primary completion date, Metastases: Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Oct 22, 2015
P2, N=42, Recruiting, Sponsor: University of Florida
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Jun 2016 --> Dec 2016
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=77, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Jun 2016 --> Oct 2016
- gedatolisib (PF-05212384) / Celcuity
Trial termination, Metastases: A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=18, Terminated, Sponsor: Pfizer
Trial primary completion date: Jun 2016 --> Oct 2016 Completed --> Terminated; B2151007 was prematurely discontinued due to Pfizer's change in prioritization for the portfolio and is not due to any safety concerns or regulatory interaction
- Trial initiation date, Metastases: Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer (clinicaltrials.gov) - Oct 22, 2015
P4, N=36, Recruiting, Sponsor: University of Chicago
Completed --> Terminated; B2151007 was prematurely discontinued due to Pfizer's change in prioritization for the portfolio and is not due to any safety concerns or regulatory interaction Initiation date: Apr 2015 --> Dec 2014